Back to search results

Study of XB371 for Advanced Solid Tumors

This study is testing a drug called XB371, given through an IV, for people with locally advanced or metastatic (spread to other parts of the body) solid tumors. The main goal is to understand how safe XB371 is and what side effects it might cause. We will be looking at dose-limiting toxicities (side effects that are severe enough to stop treatment) and any other side effects that happen during the study. You might be able to join if you are 18 or older, have solid tumors that have come back or spread, and meet certain health requirements. The study plans to enroll about 150 participants, but the current recruitment status is not clear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. Some parts of the study are randomized, where participants are assigned to a treatment group by chance, while other parts are not.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored for up to approximately 7 months after treatment begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07123103

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Exelixis
~150 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:XB371

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with a Dose-limiting Toxicity (DLT)
Measured over Up to the end of the first cycle (Up to Day 21 of a 21-day cycle)
+1 more outcome measured

Conditions

Solid Tumors

Explore related trials

Solid Neoplasm

NCT07123103

Where you'd take part

This study runs at 9 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Exelixis Clinical Site #1

    San Antonio, Texasno site contact published

    Recruiting

  • Exelixis Clinical Site #2

    Huntersville, North Carolinano site contact published

    Recruiting

  • Exelixis Clinical Site #3

    Grand Rapids, Michiganno site contact published

    Recruiting

  • Exelixis Clinical Site #4

    Orlando, Floridano site contact published

    Recruiting

  • Exelixis Clinical Site #5

    Rogers, Arkansasno site contact published

    Recruiting

  • Exelixis Clinical Site #6

    Washington D.C., District of Columbiano site contact published

    Recruiting

  • Exelixis Clinical Site #7

    New Brunswick, New Jerseyno site contact published

    Recruiting

  • Exelixis Clinical Site #8

    Houston, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Medical Director · STUDY_DIRECTOR · Exelixis

Who to contact

Exelixis Clinical Trials
[email protected]
1-888-EXELIXIS (888-393-5494)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Minimum life expectancy of ≥ 12 weeks.
Recurrent locally advanced or metastatic solid tumors.
Adequate end organ and bone marrow function.

Exclusion

Primary brain tumors or known active brain metastases, leptomeningeal, or cranial epidural disease.
History of interstitial lung disease (ILD) of any grade or history of organizing pneumonia.
Has acute ocular infection, acute or chronic ulcerative/cicatricial condition of conjunctiva or cornea.
Known history of immunodeficiency virus (HIV) unless specific criteria are met.
Active infection with hepatitis C virus (HCV) defined as positive for HCV antibody.
Major surgery within 4 weeks before the first dose of study treatment.
Received radiation therapy within 2 weeks before the first dose of study treatment.
Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study treatment.

What this trial measures

  • Number of Participants with a Dose-limiting Toxicity (DLT)Up to the end of the first cycle (Up to Day 21 of a 21-day cycle)
  • Number of Participants with a Treatment-emergent Adverse Event (TEAE)Up to approximately 7 months